PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
AssigneeAmgen Research (Munich) GmbH
InventorsPeter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
Life of this patent
Estimating the term…
Abstract
The present invention relates to a PPS for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain. Kits comprising a PPS, a CD3 binding domain and instructions for use which indicate that the PPS is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
Claims19
A method for the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain comprising administering an effective amount of pentosanpolysulfate (PPS).
A kit comprising a PPS and a CD3 binding domain and either instructions for use or an imprint indicating that the PPS is to be employed for the treatment amelioration or prophylaxis of neurological adverse events caused by said CD3 binding domain.
Dependencies are inferred from the claim text.